News & Media

Take a look inside our world

Feature stories

Out of the Limelight: Supporting Millions of Non-COVID Patients in Their Journey Back to Healthcare

Out of the Limelight: Supporting Millions of Non-COVID Patients in Their Journey Back to Healthcare

Digital Health – The new standard

Digital Health – The new standard

Celebrating Cultural Diversity at Teva

Celebrating Cultural Diversity at Teva

“One of the most important attributes for developing people is listening”

“One of the most important attributes for developing people is listening”

“This ‘invisible pandemic’ is one of the biggest global health challenges”

“This ‘invisible pandemic’ is one of the biggest global health challenges”

The secret to achieving our new environmental targets? Our people

The secret to achieving our new environmental targets? Our people

"Bringing more women and more diversity into our leadership makes us stronger."

"Bringing more women and more diversity into our leadership makes us stronger."

Meet the Expert: Professor Ruth Arnon

Meet the Expert: Professor Ruth Arnon

“The resilience of Teva’s operation never fails to surprise me”

“The resilience of Teva’s operation never fails to surprise me”

Improving access to medicines for 4000 children with cancer in Malawi

Improving access to medicines for 4000 children with cancer in Malawi

Press Releases

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once ...

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Present...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache So...

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society

Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society Internatio...

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International C

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of...

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bact

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Assoc...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the...

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Trea

Teva Reports First Quarter 2021 Financial Results

Teva Reports First Quarter 2021 Financial Results

Connect with us on social media


Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Teva Social Media Guidelines

Connect with us

Contacts for Media Inquiries

Kelley Dougherty

Corporate Communications North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Yonatan Beker

Corporate Communications Israel

+972-3-9187869
Yonatan.Beker@tevapharm.com

Smadar Tabenkin-Ezer

Corporate Communications International Markets

+972-3-9062305
Smadar.Tabenkin-Ezer01@teva.co.il

Leslie McGibbon

Corporate Communications Europe

Leslie.Mcgibbon@Tevaeu.com